Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past 70 years1 These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of the coronavirus (SARS-CoV2)-associated disease called COVID-192,3.

https://www.ncbi.nlm.nih.gov/pubmed/32241801